Compare Ascendis Pharma A/S (ASND) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Firy Inc. — how do they compare? Ascendis Pharma A/S trades at $263.15 (market cap $17.74B), while Firy Inc. trades at $8.41 (market cap $133.29M). The key difference: Ascendis Pharma A/S is far larger — about 133.1× Firy Inc.'s market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | FIRY | |
|---|---|---|
Market Cap | $17.74B | $133.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $12.45 |
52-Week Low | $163.32 | $2.28 |
Enterprise Value | $18.11B | $76.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FIRY (formerly Skillz) trades at $8.54, down 3.06% today, amid a recent rebrand and mixed quarterly results. The stock shows a bullish technical signal with support near $8 and resistance at $9, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; while technicals suggest near-term strength, fundamental challenges from sustained unprofitability and high cash burn pose significant risks. Analyst sentiment is mixed with 60% hold ratings, reflecting uncertainty over the company's turnaround amid competitive pressures in mobile gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
